From GlobeNewswire: 2025-05-18 07:25:00

Intellia Therapeutics, Inc. presented positive two-year follow-up data from the Phase 1 trial of nex-z for hereditary ATTR amyloidosis with polyneuropathy. Patients showed deep, durable serum TTR reduction and improvements in neuropathic impairment measures, including those previously on patisiran. The ongoing Phase 3 MAGNITUDE-2 trial aims to measure clinical outcomes and evaluate the reduction in serum TTR following a single dose of nex-z to potentially support a BLA submission by 2028. Safety data remains favorable with generally well-tolerated adverse events. Enrollment in the MAGNITUDE-2 study is progressing well.



Read more at GlobeNewswire: Intellia Announces Positive Two-Year Follow-Up Data from